C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 209/88 (2006.01) A61K 31/343 (2006.01) A61K 31/381 (2006.01) A61K 31/403 (2006.01) A61P 3/04 (2006.01) A61P 3/06 (2006.01) A61P 3/10 (2006.01) C07D 307/91 (2006.01) C07D 333/76 (2006.01)
Patent
CA 2394778
Compounds of general formula (I) are useful in the treatment and prevention of .beta.3-related diseases including diabetes, obesity and hypertention wherein R1 is hydrogen, halogeno, or hydroxyl; R2 is lower alkyl or benzyl; R3 is OR, halogeno, trifluoromethyl, lower alkyl, lower acyl, NR4R4', nitro, or cyano; R is hydrogen, lower alkyl, benzyl, or optionally substituted lower acyl; R4 and R4' are each independently hydrogen, lower alkyl, lower acyl, benzyl, or - SO2R5; R5 is lower alkyl or benzyl; W is oxygen, a secondary nitrogen atom (NH), or sulfur; and * represents an asymmetric carbon atom.
L'invention concerne des composés de formule générale (I), utiles dans le traitement et la prévention de maladies associées à .beta.3, dont le diabète, l'obésité et l'hypertension. Dans la formule (I), R?1¿ représente hydrogène, halogéno ou hydroxyle ; R?2¿ représente benzyle ou alkyle inférieur ; R?3¿ représente OR, halogéno, trifluorométhyle, alkyle inférieur, acyle inférieur, NR?4¿R?4¿, nitro ou cyano ; R représente hydrogène, alkyle inférieur, benzyle ou acyle inférieur éventuellement substitué ; R?4¿ et R?4'¿ représentent chacun indépendamment hydrogène, alkyle inférieur, acyle inférieur, benzyle ou SO¿2?R?5¿ ; R?5¿ représente benzyle ou alkyle inférieur ; W représente oxygène, un atome d'azote secondaire (NH), ou soufre ; et * représente un atome de carbone asymétrique.
Miyoshi Shiro
Ogawa Kohei
Asahi Kasei Kabushiki Kaisha
Goudreau Gage Dubuc
LandOfFree
Novel substituted tricyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel substituted tricyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel substituted tricyclic compounds will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1472394